

# Heatwave-associated *Vibrio* infections in Germany, 2018 and 2019

Thomas Theo Brehm<sup>1,2,3</sup>, Laura Berneking<sup>3,4</sup>, Meike Sena Martins<sup>5</sup>, Susann Dupke<sup>6</sup>, Daniela Jacob<sup>6</sup>, Oliver Drechsel<sup>7</sup>, Jürgen Bohnert<sup>8</sup>, Karsten Becker<sup>8</sup>, Axel Kramer<sup>9</sup>, Martin Christner<sup>4</sup>, Martin Aepfelbacher<sup>2,4</sup>, Stefan Schmiedel<sup>1,2</sup>, Holger Rohde<sup>2,4</sup>, the German *Vibrio* Study Group<sup>10</sup>

1. Division of Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2. German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany
3. These authors contributed equally to this article and share first authorship
4. Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
5. Institut für Meereskunde, Centrum für Erdsystemwissenschaften und Nachhaltigkeit, University Hamburg, Hamburg, Germany
6. Robert Koch Institute, ZBS 2: Centre for Biological Threats and Special Pathogens, Highly Pathogenic Microorganisms, Berlin, Germany
7. Robert Koch Institute, MF1: Bioinformatics, Berlin, Germany
8. Friedrich Loeffler-Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany
9. Institute of Hygiene and Environmental Medicine, University Medicine Greifswald, Greifswald, Germany
10. The members of the Study Group are listed at the end of the article

**Correspondence:** Thomas Theo Brehm (t.brehm@uke.de)

**Investigators:** the investigators are listed at the end of the article

#### Citation style for this article:

Brehm Thomas Theo, Berneking Laura, Sena Martins Meike, Dupke Susann, Jacob Daniela, Drechsel Oliver, Bohnert Jürgen, Becker Karsten, Kramer Axel, Christner Martin, Aepfelbacher Martin, Schmiedel Stefan, Rohde Holger, the German *Vibrio* Study Group. Heatwave-associated *Vibrio* infections in Germany, 2018 and 2019. *Euro Surveill.* 2021;26(41):pii=2002041. <https://doi.org/10.2807/1560-7917.ES.2021.26.41.2002041>

Article submitted on 04 Dec 2020 / accepted on 15 Apr 2021 / published on 14 Oct 2021

**Background:** *Vibrio* spp. are aquatic bacteria that prefer warm seawater with moderate salinity. In humans, they can cause gastroenteritis, wound infections, and ear infections. During the summers of 2018 and 2019, unprecedented high sea surface temperatures were recorded in the German Baltic Sea. **Aim:** We aimed to describe the clinical course and microbiological characteristics of *Vibrio* infections in Germany in 2018 and 2019. **Methods:** We performed an observational retrospective multi-centre cohort study of patients diagnosed with domestically-acquired *Vibrio* infections in Germany in 2018 and 2019. Demographic, clinical, and microbiological data were assessed, and isolates were subjected to whole genome sequencing and antimicrobial susceptibility testing. **Results:** Of the 63 patients with *Vibrio* infections, most contracted the virus between June and September, primarily in the Baltic Sea: 44 (70%) were male and the median age was 65 years (range: 2–93 years). Thirty-eight patients presented with wound infections, 16 with ear infections, six with gastroenteritis, two with pneumonia (after seawater aspiration) and one with primary septicaemia. The majority of infections were attributed to *V. cholerae* (non-O1/non-O139) (n=30; 48%) or *V. vulnificus* (n=22; 38%). Phylogenetic analyses of 12 available isolates showed clusters of three identical strains of *V. vulnificus*, which caused wound infections, suggesting that some clonal lines can spread across the Baltic Sea. **Conclusions:** During

the summers of 2018 and 2019, severe heatwaves facilitated increased numbers of *Vibrio* infections in Germany. Since climate change is likely to favour the proliferation of these bacteria, a further increase in *Vibrio*-associated diseases is expected.

## Introduction

The genus *Vibrio*, which belongs to the family *Vibrionaceae* and the class *Gammaproteobacteria*, includes many species that are potential human pathogens [1]. *V. cholerae* is a highly diverse species that consists of more than 200 serogroups [2]. Strains within the serogroups O1 and O139 produce cholera toxin and are the causative agents of endemic and epidemic cholera, which represent an important cause of morbidity and mortality in countries with inadequate access to clean water and sanitation facilities [3]. *V. cholerae* strains not included in these serogroups as well as other *Vibrio* spp. are referred to as non-cholera *Vibrio* spp. and are ubiquitous aquatic bacteria with a worldwide distribution, especially in warm estuarine and marine ecosystems [2]. These halophilic bacteria prefer low to moderate salinity (less than 25 parts per thousand (ppt) NaCl) [4]. The abundance of *Vibrio* spp. in marine and estuarine waters closely corresponds with the sea surface temperatures (SSTs) since they proliferate in warm water [5]. Thus, regional variations in environmental conditions are paramount importance in understanding the ecology of *Vibrio* spp.

TABLE 1

Characteristics of patients with domestically-acquired *Vibrio* spp. infections by age group, Germany, 2018 and 2019 (n = 63)

Characteristic	Total (n = 63)	Wound infections (n = 38)	Ear infections (n = 16)	Gastroenteritis (n = 6)	Pneumonia (n = 2)	Primary septicaemia (n = 1)
Age in years, Median (range)	65 (2–93)	69 (7–93)	13 (3–78)	60 (2–88)	73 (68–78)	88
Sex						
Male	44	26	10	5	2	1
Female	19	12	6	1	0	0
<i>Vibrio</i> spp.						
<i>V. cholerae</i> (non-O1/non-O139)	30	9	15	5	0	1
<i>V. vulnificus</i> <sup>a</sup>	24	22	0	0	2	0
<i>V. parahaemolyticus</i> <sup>a</sup>	5	4	1	0	0	0
<i>V. fluvialis</i>	3	2	0	1	0	0
<i>V. alginolyticus</i>	2	2	0	0	0	0
Comorbidities						
Information available	41	33	5	1	2	0
Chronic disease	25	22	0	1	2	0
Immunosuppression <sup>b</sup>	8	6	0	1	1	0
Course of disease						
Information available (n)	41	33	5	1	2	0
Antibiotic treatment	37	32	2	1	2	0
Hospital admission	35	31	1	1	2	0
Intensive care unit admission	21	18	0	1	2	0
Death	8	6	0	1	1	0

<sup>a</sup> One patient was co-infected with *V. vulnificus* and *V. parahaemolyticus*, which were detected in wounds as well as in blood cultures.

<sup>b</sup> Immunosuppression was the result of immunosuppressive therapy, underlying haematological malignancies, or splenectomy.

Human infections with non-cholera *Vibrio* spp. can manifest as wound infections, ear infections, gastroenteritis, and primary septicaemia and have been predominantly reported in tropical and subtropical regions [6]. In Europe, cases are rare, and infections associated with the Mediterranean Sea [7-9], the Atlantic Ocean [10-12], or the Baltic Sea [13,14] have only been sporadically reported. However, a rapidly warming marine environment accompanied by an increase in extreme weather events such as heatwaves has resulted in unprecedented peak SSTs favouring the spread of *Vibrio* spp. worldwide. Recently, larger *Vibrio* spp. outbreaks have been reported in temperate regions such as Spain [15], Sweden, and Finland [16]. In Germany, *Vibrio* spp. other than toxigenic *V. cholerae* strains were not classified as reportable pathogenic agents before March 2020; to date, only a few cases have been reported and few case series of autochthonous infections have been published [17-20]. Over the last decades, resistance to various antibiotics, including to ampicillins, tetracyclines, and carbapenems, has emerged among *Vibrio* spp [21,22]. As a result of resistant isolates, the monitoring of antibiotic profiles of clinical and environmental *Vibrio* spp. has become of increasing importance. However, information on the number of human cases and the

abundance of *Vibrio* spp. in coastal waters is scarce in most other European countries.

When we became aware of a high number of human infections with virulent *Vibrio* strains contracted in the Baltic Sea during the summer months of 2018 and 2019 (data not shown), we decided to conduct an observational retrospective multi-centre cohort study of domestically-acquired *Vibrio* infections. This study describes the epidemiology and the clinical impact of those infections and assesses antibiotic resistance patterns and phylogenetic relationships among clinical isolates. To determine the association between *Vibrio* infections and SST anomalies, we analysed the degree of warming in the south-western Baltic Sea, where the majority of the infections occurred.


## Methods

### Study population

Although non-cholera *Vibrio* spp. were not notifiable pathogenic agents in Germany before March 2020, clinical isolates of *V. cholerae* could be submitted to the Unit of Highly Pathogenic Microorganism (ZBS 2) at the Center for Biological Threats and Special Pathogens at

**FIGURE 1**

Monthly distribution of patients with domestically-acquired *Vibrio* spp. infections, Germany 2018 and 2019



Infections spiked during summer heat waves in the Baltic Sea area.

the Robert Koch Institute (RKI), Germany's national public health institute, for confirmation and serotyping. In addition, clinical isolates of other virulent *Vibrio* spp. could be sent for further analysis to the consultant laboratory for *Vibrio* spp. at the Federal Institute for Risk Assessment (BfR).

To identify as many patients with *Vibrio*-associated diseases as possible, the first author contacted the RKI, the BfR, and hospitals and microbiological laboratories within 20 km of the German North Sea or Baltic Sea coastline. Patients with *Vibrio* infections and a recent history of foreign travel who presumably did not acquire those infections in Germany were not included in the analysis. We (TTB, LB, HR) developed a standardised case report form, which was used to obtain demographic and clinical characteristics of patients from the treating hospitals and physicians.

### Laboratory investigations

Antibiotic susceptibility testing and whole genome sequencing (WGS) of *V. cholerae* isolates initially submitted to the Unit of Highly Pathogenic Microorganisms (ZBS 2) at the Centre for Biological Threats and Special Pathogens at the RKI by microbiological laboratories or hospitals were performed directly at the RKI. All other isolates were analysed at the Institute of Medical Microbiology, Virology and Hygiene at the University Medical Center Hamburg-Eppendorf.

Species isolates were confirmed by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI-TOF) fingerprinting using a biotyper instrument (Bruker Daltonics, Bremen, Germany). To verify a *V. cholerae* species-specific sequence of *sodB* gene (superoxide dismutase), multiplex real-time PCR ( $\zeta$  nuclease assay) was performed on all suspected isolates. The same assay confirmed the lack of *ctxA*, the encoding cholera toxin produced by toxigenic *V. cholerae*. In addition, conventional PCRs for the determination of serotype serogroup-specific gene *rfb* were performed to confirm the identification of non-O:1/non-O:139 *V. cholerae* strains. Primers and probes were used as previously described [23].

### Antibiotic susceptibility testing

Available *Vibrio* isolates were subjected to antimicrobial susceptibility testing (AST) using disk diffusion and classified according to Clinical and Laboratory Standards Institute (CLSI) breakpoints [24]. Briefly, *Vibrio* isolates were grown on Colombia sheep blood agar at 37°C for 18 hours. A colony suspension equivalent to 0.5 McFarland was prepared in 0.85% NaCl, streaked on Müller Hinton agar (MHA) plates, and incubated with respective antimicrobial agent disks at 35±2°C for 18 hours. Sixteen types of antibiotics disks (Oxoid by Thermo Fischer Scientific, Waltham, USA) were used: ampicillin (10 µg), amoxicillin-clavulanic acid (20/10 µg), piperacillin-tazobactam (100/10 µg), amikacin (30 µg), cefepime (30 µg), cefuroxime (30 µg), cefotaxime (30 µg), ceftazidime (30 µg), gentamicin (10 µg), imipenem (10 µg), meropenem (10 µg), ciprofloxacin (5 µg), levofloxacin (5 µg), chloramphenicol (30 µg), sulfamethoxazole/trimethoprim (1.25/23.75 µg), and tetracycline (30 µg). *Escherichia coli* ATCC 25922 was included as a positive control in each test. After incubation, the inhibition zone was measured and interpreted based on guidelines of CLSI M45-A2 [24]. Results for disk diffusion testing are shown in Supplementary Table S1.

### Whole genome sequencing

WGS was performed retrospectively with an Illumina NextSeq instrument (Illumina, San Diego, USA) using 2 x 150 bp paired-end chemistry. Sequencing reads have been deposited in NCBI's small reads archive (BioProject: PRJNA723758). Processing of WGS data for further phylogenetic analysis was performed at the Institute of Medical Microbiology, Virology and Hygiene at the University Medical Center Hamburg-Eppendorf. Reads were assembled with shovill 1.0.4 (<https://github.com/tseemann/shovill>) and spades 3.13.1 [25] and annotated with prokka 1.13.3 [26]. An average nt identity over 80% with genomes of the respective reference genome strains (*Vibrio fluvialis*\_ASM155841v2; *Vibrio parahaemolyticus*\_ASM19609v1; *Vibrio vulnificus*\_ASM221513v1; *Vibrio cholera* ASM674v1; and *Vibrio alginolyticus* ASM35417v2) confirmed the identified species [27]. Sequencing reads were initially mapped to the respective reference genome and variants were called using snippy (<https://github.com/tseemann/snippy>). An alignment of core genome single nucleotide polymorphisms (SNPs) was produced in snippy to infer a phylogeny. The phylogenetic tree was constructed with Molecular Evolutionary Genetic Analysis (MEGA) X version 10.2.0 [28] using a neighbour-joining algorithm [29]. Possible relationships between clusters, potential genotypic, and phenotypic traits associated with pathogenicity and source of isolation were investigated. The virulence gene profile was determined with ABRicate (<https://github.com/tseemann/abricate>) and an additional blast-search against the virulence factor database [30].

**TABLE 2**Deaths from *Vibrio* spp. infections, Germany, 2018 and 2019 (n = 8)

Year	Age group in years	<i>Vibrio</i> spp.	Clinical manifestation	Chronic disease	Immuno-suppression
2018	80–89	<i>V. vulnificus</i>	Wound infection	yes	yes
2018	70–79	<i>V. vulnificus</i>	Wound infection	yes	no
2018	70–79	<i>V. vulnificus</i>	Wound infection	yes	yes
2019	80–89	<i>V. cholerae</i> (non-O1/non-O139)	Gastroenteritis after eating crab meat	yes	yes
2019	80–89	<i>V. vulnificus</i>	Wound infection	yes	no
2019	60–69	<i>V. vulnificus</i>	Pneumogenic sepsis after drowning accident	no	no
2019	>90	<i>V. vulnificus</i>	Wound infection	yes	no
2019	50–59	<i>V. vulnificus</i>	Wound infection	yes	no

### Climatological analyses

SST data were originally derived using the near-infrared channel of the space-borne Advanced Very High Resolution Radiometer (AVHRR) satellite. We used the Reynolds Optimum Interpolation Sea Surface Temperature (OISST) data set with a spatial resolution of ca 25 km. The daily data were obtained from National Oceanic and Atmospheric Administration's (NOAA) National Center for Environmental Information (NCEI) [31]. The annual climatological cycle from 1982 to 2001 was calculated using the OISST as a reference. SST anomalies were calculated from the higher resolving Moderate Resolution Imaging Spectroradiometer (MODIS) SST data, which have been available since 2002 from the MODIS sensors onboard the EOS-AQUA and Terra satellites. The MODIS Aqua SST data (version 2019 Reprocessing, NASA OB.DAAC, Greenbelt, USA) were provided with a time variable by the Integrated Climate Data Center (ICDC) at the University of Hamburg, Germany. The MODIS sensors offer a spatial resolution of 4.6 km; however, because the sensors cannot penetrate clouds, the data coverage is reduced. The annual climatology from the OISST data was interpolated to the higher resolution of the MODIS data and subtracted from the MODIS SST time series. In addition, a daily MODIS SST spatial average was calculated for the German coastlines where the infections in our study population occurred. The trend in SSTs was calculated from the low-passed SSTs (19 months) by a simple linear regression using standard statistics. Only values with a significance of  $p < 0.05$  were considered.

### Ethical statement

The study was reviewed and approved by the Ethics Committee of the Medical Council of Hamburg (PV7066) and written informed consent was waived because of the retrospective design.

### Results

#### Patients and course of disease

Of the 63 patients with domestically-acquired *Vibrio* infections, 44 (70%) were male and the median age for all patients was 65 years (range:

2–93 years). Reliable anamnestic information about the precise place of infection was available for 36 patients, all of whom contracted *Vibrio* infections after recreational exposure to the open Baltic Sea or its estuaries (n=34) or after consumption of shrimp caught in the North Sea or the Baltic Sea (n=2). Nine patients were diagnosed while hospitalised near the Baltic Sea, so it is highly likely that their infections occurred during exposure to the Baltic Sea. For the remaining 18 patients, the place of infection is not known. A total of 38 patients (60%) presented with wound infections, 16 (25%) with ear infections, and six (10%) with gastroenteritis (Table 1).

The vast majority of infections occurred in the summer months between June and September (n=54; 86%) (Figure 1). In addition, nine infections with *V. cholerae* (non-O1/non-O139) occurred between October and April. Among these cases, detailed information on the route of transmission was only available for one patient, who contracted a wound infection after bathing in the Baltic Sea in October. However, no foreign travel was documented for these cases, so it can be assumed that these sporadic infections were acquired in Germany.

Among patients who contracted wound infections, the majority (n=32; 84%) had traumatic injuries either before or during contact with contaminated seawater. Another patient had superficial skin lesions as the result of mosquito bites, which served as an entry point for the *Vibrio* spp. In addition, five patients had underlying chronic skin diseases, including diabetic foot syndrome, lymphoedema, and atopic dermatitis, which predisposed them for wound infections.

Twenty-one patients with wound infections and one patient with gastroenteritis developed septicaemia, suggesting systemic disease progression. In addition, two patients developed pneumonia after seawater aspiration, and one patient presented with primary septicaemia without a known primary focus of infection. Wound infections and primary septicaemia mainly occurred in elderly patients (median age 69 and 78

TABLE 3

Phenotypic antibiotic susceptibilities and associated genetic resistance markers in isolates from patients with *Vibrio* spp. infections, Germany, 2018 and 2019 (n = 48 isolates)

Antibiotic	Phenotypic susceptibility (n = 47)				Resistance detected by WGS (n = 47)		
	Resistant		Intermediate		Gene or mutation	Positive	
	n	%	n	%		n	%
AMK	2	4.3	11	23.4	NA	0	0
AMP	6	12.8	3	6.4	<i>bla</i> <sub>CARB-7</sub>	2	4.3
AMC	1	2.1	2	4.3	<i>bla</i> <sub>CARB-18</sub> , <i>bla</i> <sub>CARB-21</sub> , <i>bla</i> <sub>CARB-26</sub> , <i>bla</i> <sub>CARB-30</sub> , <i>bla</i> <sub>CARB-42</sub>	7	14.9
MEM	0	0	0	0	<i>varG</i>	15	31.9
TET	0	0	0	0	<i>tet</i> <sub>34</sub> , <i>tet</i> <sub>35</sub>	18	38.3
GEN	1	2.1	0	0	NA	0	0

AMC: amoxicillin-clavulanic acid; AMK: amikacin; AMP: ampicillin; GEN: gentamicin; MEM: meropenem; NA: not applicable; TET: tetracycline; WGS: whole genome sequencing.

years, respectively), and ear infections mainly occurred in younger patients (median age 13 years).

Information about the medical history and the course of disease was available for 65% (n = 41) of all patients. The most prevalent comorbidities were cardiovascular diseases (n = 25) and diabetes mellitus (n = 8). Eight patients were immunocompromised because of immunosuppressive therapy, underlying haematological malignancies, or splenectomy. The vast majority of patients had received antibiotic therapy (n = 37) and required hospitalisation (n = 35) with a mean time of hospitalisation of 18 days. Admission to an intensive care unit (ICU) was necessary for 21 patients. Eight patients died of the infection (Table 2).

All but one of these eight patients were male, and the median age was 80 years (range: 56–93 years). Six patients died of wound infections from *V. vulnificus*, one patient died of gastroenteritis from *V. cholerae* (non-O1/non-O139) after eating crab meat, and one patient died of pneumonia from *V. vulnificus* after aspirating seawater. Of the patients who died of infection, three were immunocompromised and all but one had chronic diseases.

### Detected clinical *Vibrio* spp. isolates

Most infections were either attributed to *V. cholerae* (non-O1/non-O139) (n = 30; 48%) or *V. vulnificus* (n = 24; 38%) (Table 1). Less frequently, *V. parahaemolyticus* (n = 5; 8%), *V. fluvialis* (n = 3; 5%), and *V. alginolyticus* (n = 2; 3%) were detected.

Ear infections were primarily caused by *V. cholerae* (non-O1/non-O139) (n = 15/16), and wound infections were primarily caused by *V. vulnificus* (n = 22/38). One patient was infected with both *V. vulnificus* and *V. parahaemolyticus*; both species were detected in the wounds and in the blood cultures. One patient was diagnosed with polymicrobial ear infections with *V. parahaemolyticus* and *Shewanella putrefaciens*, and one patient was diagnosed with *V.*

*cholerae*, *Staphylococcus aureus*, *Pseudomonas stutzeri*, and *E. coli*.

A total of 48 clinical *Vibrio* spp. isolates (*V. cholerae* (non-O1/non-O139), n = 29; *V. vulnificus*, n = 12; *V. parahaemolyticus*, n = 3; *V. alginolyticus*, n = 2; and *V. fluvialis*, n = 1) were available for further analysis and subsequently subjected to AST and WGS. One *V. vulnificus* isolate was only available for AST but not WGS, and one *V. vulnificus* isolate was only available for WGS but not for AST.


### Antimicrobial susceptibilities

Most of the 16 antibiotics tested in this study – e.g., tetracycline, third-generation cephalosporins (cefotaxime and ceftazidime), aminoglycosides (gentamicin and amikacin), and fluoroquinolones (ciprofloxacin and levofloxacin) – are recommended by the United States Centers for Disease Control and Prevention (CDC) for the treatment of *Vibrio* spp. infections [32]. Based on the AST results, the highest rate of phenotypic antimicrobial resistance of all *Vibrio* spp. isolates in our study were detected for ampicillin (n = 6) and amikacin (n = 2). Low rates of resistance were found for gentamicin (n = 1) and amoxicillin-clavulanic acid (n = 1). However, all isolates were susceptible to cefepime, cefotaxime, ceftazidime, cefuroxime, chloramphenicol, ciprofloxacin, gentamicin, imipenem, meropenem, levofloxacin, and trimethoprim-sulfamethoxazole (Supplementary Table S1).

Resistance gene profiling identified resistance genes in 72% (34/47) of all *Vibrio* spp. isolates (Table 3). In all but one ampicillin-resistant isolate, *bla*<sub>CARB</sub> genes encoding for a beta-lactamase were detected (*bla*<sub>CARB-7</sub>; n = 2). One of these isolates showed additional resistance to amoxicillin-clavulanic acid. Gentamicin-resistance is mostly conferred by aminoglycoside-modifying enzymes. However, no corresponding resistance gene was found for gentamicin-resistant and gentamicin-intermediate resistant isolates.

**FIGURE 2**

Maximum likelihood trees showing phylogenetic relationships of 13 *Vibrio vulnificus* genomes based on SNP analysis



SNP: single nucleotide polymorphism.


The *V. vulnificus* ASM221513v1 sequence was used as reference. Bar, 2% estimated sequence divergence.

Genomical analysis showed that *varG*, which encodes a metallo-beta-lactamase, was present in 31% (n = 15/29) of *V. cholerae* (non-O1/O139) isolates. VarG has beta-lactamase activity against penicillins, cephalosporins, and carbapenems, with the highest activity against meropenem [33], but no meropenem resistance was detected in our study isolates. Two *V. cholerae* (non-O1/non-O139) isolates additionally carried variants of *bla*<sub>CARB-7</sub>, a determinant of beta-lactam resistance.

The prevalence of antibiotic resistance genes *tet34* and *tet35* indicates intrinsic resistance to tetracycline, and these genes are present in all *V. vulnificus* and *V. parahaemolyticus* strains [34]. The function of *tet34* is associated with xanthine-guanine phosphoribosyltransferase (XPRT)-like activity and has been shown to be present in certain *Vibrio* spp [35]. However, the phenotype of antimicrobial resistance indicates that all strains are sensitive to tetracycline, suggesting that *tet34* is potentially non-functional [36].

**FIGURE 3**

Maximum likelihood trees showing phylogenetic relationships of 28 *Vibrio cholerae* genomes based on SNP analysis



SNP: single nucleotide polymorphism.

The *V. cholerae* ASM674v1 sequence was used as reference. Bar, 5% estimated sequence divergence.

### Phylogenetic data

The genetic diversity of *V. vulnificus* isolates (n=12) and *V. cholera* (non-O1/non-O139) isolates (n=29) was evaluated using a phylogenomic tree based on single nucleotide polymorphisms (SNPs) (Figure 2 and 3). Despite the genomic divergence among clusters, no distinct patterns linking strain phylogeny, isolation source, or virulent capabilities were apparent. As the isolates within the same clade were closely

related, we identified isolates that were identical in the detected SNPs, but mostly with different isolation sources. Virulence gene profiling did not reveal atypical virulence factors (e.g., toxins) in our study isolates (Supplementary Table S2).


### Climatological data

Between 1982 and 2019, the SST warming trend in the south-western Baltic Sea (Box in Figure 4A) was 0.56 °C


## FIGURE 4

### Sea surface temperatures in the south-eastern Baltic Sea in 2018 and 2019

A. Satellite-derived sea surface temperature (SST) anomaly (August 2018)



B. The climatological mean annual cycle of SST (1982–2019)



4A: Satellite-derived sea surface temperature (SST) anomaly in August 2018 with a reference to the climatological mean between 1982 and 2001. The thin black line shows the water depth of 10 m and reveals the shallow coastal areas. 4B: The climatological mean annual cycle of SST (black) based on data between 1982 and 2019 and averaged within the black rectangular box in 4A with the standard deviation underlaid as a grey shadow. The annual SSTs between 2018 and 2019 are shown in blue and pink as indicated in the legend.

per decade. During this period, the Baltic Sea reached the highest SST in August 2018 (Figure 4A). The positive SST anomaly reached 2°C throughout the south-western Baltic Sea. In the central-southern Baltic Sea and in some coastal areas, especially the eastern coasts with shallow areas, the positive SST anomaly even reached 5°C. Although the SSTs in 2019 were not as high as in the summer of 2018, positive SST anomalies of up to 4°C were observed in 2019, primarily in June and September (Figure 4B).

## Discussion

Here, we present a large case series of domestically-acquired *Vibrio* infections in Germany. Consistent with previous studies [37,38], we demonstrate the broad clinical spectrum and various disease manifestations of *Vibrio* infections, ranging from mild gastroenteritis or ear infections to fulminant wound infections and primary septicæmia.

Also in line with previous findings, we observed a striking male predominance among patients with *Vibrio* infections [16,37]. While this may be attributed to sex differences in predisposing comorbidities and the choice of recreational activities, it has also been suggested that female sex hormones may have a protective effect against severe *V. vulnificus* infections [39]. Our study further emphasises that *Vibrio* infections occur across all age groups, but different disease manifestations have different age distributions. While ear infections most commonly affected children, wound infections and primary septicæmia were predominantly detected in elderly

patients. The high prevalence of immunocompromising conditions and the chronic medical conditions among patients in our study cohort in general and in those who died of the infection in particular suggest these conditions may be determinants of disease severity in patients who contract *Vibrio* infections [37].

Importantly, recreational exposure to the Baltic Sea and its estuaries was responsible for the majority of infections in our study cohort. As in other studies, this finding demonstrates that most infections with *Vibrio* spp. involve either exposure of previously contracted wounds to seawater or injuries acquired during water-based activities [9,37]. The vast majority of *Vibrio* infections (n=54; 86%) occurred between June and September: when water-associated recreational activities increase, high SSTs are responsible for an elevated abundance of *Vibrio* spp. in coastal waters. Sporadic infections outside these months were all caused by *V. cholerae* (non-O1/non-O139), which has a higher probability of occurrence at relatively low water temperatures compared to other *Vibrio* spp [4,40].

As the result of global warming, the SSTs in the Baltic Sea are expected to rise between 4 and 5°C over the next several decades [41], which will likely lead to an increase of virulent *Vibrio* strains in coastal waters. On an interannual scale, the main driving force behind the Baltic Sea warming is the varying ambient temperature; less important are the intensity of solar radiation and the varying wind forces [42]. On a seasonal scale, the SSTs in the Baltic Sea are characterised by an average amplitude of 16 to 18°C between summer and winter



temperatures, which is higher in shallow bays and coastal regions as bathymetry prevents mixing and circulation of the water [43]. In addition, the rise of sea levels is expected to cause more coastal flooding, which will expand estuarine and brackish water environments suitable for *Vibrio* spp. growth [44]. Recently, early warning systems have been established that can forecast the environmental suitability of coastal waters for *Vibrio* spp. growth using remotely sensed SSTs and sea surface salinity measurements [40]. These systems can be used to alert healthcare providers and individuals at risk. Importantly, infection risk from *Vibrio* spp. does not correlate with faecal indicator organisms and therefore common water surveillance practices cannot predict infection risk from *Vibrio* spp [45]. To prevent severe infections, patients with open wounds or chronic skin diseases, especially those with underlying immunocompromising conditions, should be advised to avoid contact with seawater in the Baltic and Northern Sea area when water temperatures exceed 20°C. In addition, vaccine candidates are being developed that may prevent *Vibrio* spp. infections in vulnerable populations [46].

Given the potentially fulminant disease course, patients with a presumptive diagnosis of severe *Vibrio*-associated diseases such as wound infections or primary septicæmia should promptly receive appropriate antibiotics for optimal disease outcomes. Recommended empiric treatment regimens include third-generation cephalosporins and either tetracyclines or fluoroquinolones [47]. In this study, the proportion of resistance among *Vibrio* spp. was comparable to a similar survey conducted on environmental isolates from marine coastal waters in Germany [22]. Using AST and WGS, we were able to show that empirical therapy would have been effective in all investigated cases. Resistance gene profiling identified some beta-lactamase and tetracycline inactivation enzyme genes, but no specific antimicrobial resistance patterns among *Vibrio* spp. isolates were detected that could pose a public health risk. Studies have shown that some strain subgroups are more likely to cause disease in humans than other subgroups, which is consistent with phylogenetic studies that show evidence of clustering of human isolates [48]. According to the SNP analysis, the strains showed three identical clusters for *V. vulnificus*, which caused wound infections. These clusters were found in three areas of the Baltic Sea coast, suggesting that clonal lines can spread across the Baltic Sea. However, because the number of reported *Vibrio*-associated diseases was relatively low, we could perform a phylogenetic analysis only between a small number of *V. vulnificus* and *V. cholerae* strains. Nevertheless, the results of the present survey provide an important resource for future prospective studies that focus on the emergence of *Vibrio* spp. infections contracted in the Baltic Sea and its estuaries.

Our study is subject to several limitations. First, it is not always possible to retrospectively differentiate bacterial

colonisation from infection in patients with *Vibrio* spp. detected in wound or ear swabs after recent contact with seawater, especially in individuals with more than one potentially pathogenic agent. However, in patients with a typical clinical presentation and detection of human pathogenic *Vibrio* spp., the bacterium is highly likely the causative pathogen. Second, since non-cholera *Vibrio* spp. were not notifiable in Germany in 2018 and 2019, we aimed to contact all hospitals and microbiological laboratories near the German Baltic Sea and Northern Sea; however, this data collection approach meant that *Vibrio* infections detected elsewhere were probably not captured. In addition, patients with self-limiting and transient infections may not have undergone microbiological testing or sought medical attention. Although this selection bias may result in overestimation of disease severity in our study cohort, the actual clinical burden associated with *Vibrio* infections may be grossly underestimated due to under-reporting and underdiagnosis. Third, we were not able to obtain reliable information on comorbidities, disease course, and place of infection from all patients. These limitations underscore the need for mandatory standardised surveillance systems for *Vibrio* spp. infections [2,6,49]. In Germany, a mandatory notification for *Vibrio* spp. infections has been in place since March 2020. In 2020, only 13 *Vibrio* spp. infections were reported to the RKI. This relatively low number of cases was probably the result of restrictions imposed during the coronavirus disease (COVID-19) pandemic. In the future, this mandatory surveillance may help capture comprehensive clinical and microbiological data. These data are paramount for obtaining the precise epidemiological and clinical impact of domestically-acquired *Vibrio* infections, identifying vulnerable populations, and guiding future public health preparedness activities.

## Conclusion

Our study suggests that severe heatwaves during the summer of 2018 and 2019 were responsible for at least 63 *Vibrio* spp. infections contracted in the German Baltic Sea and its estuaries. Since global warming is predicted to favour the proliferation of these bacteria in the aquatic environment and demographic change will likely increase the number of vulnerable individuals, a rise in severe *Vibrio*-associated diseases may be expected in the future. Although the burden of disease from *Vibrio* spp. infections is currently relatively low, the potentially fulminant disease course in patients with wound infections and primary septicæmia underlines the need to protect vulnerable population groups.

## German *Vibrio* Study Group

Veronika Balau, Elsa Baufeld, Simone Brechmann, Lutz Briedigkeit, Stephan Diedrich, Ulrike Ebert, Helmut Fickenscher, Bojana Grgic, Claus-Dieter Heidecke, Peter Hinz, Ada Hoffmann, Meike Holbe, Ralf Ignatius, Olaf Kaup, Martin Kern, Martina Kerwat, Ingo Klempien, Georg Lamprecht, Astrid Meerbach, Alexander Mischnik, Andreas Podbielski,

Stephan Schaefer, Roman Schwarz, Eckhard Strauch, Philipp Warnke, Simone Weikert-Asbeck, Maria Witte, Waleed Zaki

## Acknowledgements

Funding statement : TTB is funded by the German Center for Infection Research (DZIF).

## Conflict of interest

None declared.

## Authors' contributions

TTB, LB, SD, SS and HR initiated the study. MSM, DJ, OD, JB, KB, AK, MC and MA contributed to the acquisition and interpretation of data. All German *Vibrio* Study Group members contributed to acquisition of data. TTB, LB, MSM and HR wrote the first draft manuscript. All authors, including the German *Vibrio* Study Group members, critically revised the manuscript and approved the final version.

## References

- Farmer JJ. The Family Vibrionaceae. In: Dworkin M, Falkow S, Rosenberg E, Schleifer K-H, Stackebrandt E, editors. The prokaryotes: Volume 6: proteobacteria: gamma subclass. New York, NY: Springer New York; 2006. p. 495-507.
- Baker-Austin C, Trinanés J, González-Escalona N, Martínez-Urtaza J. Non-cholera *Vibrios*: the microbial barometer of climate change. *Trends Microbiol*. 2017;25(1):76-84. <https://doi.org/10.1016/j.tim.2016.09.008> PMID: 27843109
- Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J. Cholera. *Lancet*. 2017;390(10101):1539-49. [https://doi.org/10.1016/S0140-6736\(17\)30559-7](https://doi.org/10.1016/S0140-6736(17)30559-7) PMID: 28302312
- Muhling BA, Jacobs J, Stock CA, Gaitan CF, Saba VS. Projections of the future occurrence, distribution, and seasonality of three *Vibrio* species in the Chesapeake Bay under a high-emission climate change scenario. *Geohealth*. 2017;1(7):278-96. PMID: 32158993
- Baker-Austin C, Trinanés JA, Taylor NGH, Hartnell R, Siitonen A, Martínez-Urtaza J. Emerging *Vibrio* risk at high latitudes in response to ocean warming. *Nat Clim Chang*. 2012;3(1):73-7. <https://doi.org/10.1038/nclimate1628>
- Baker-Austin C, Oliver JD, Alam M, Ali A, Waldor MK, Qadri F, et al. *Vibrio* spp. infections. *Nat Rev Dis Primers*. 2018;4(1):8. <https://doi.org/10.1038/s41572-018-0005-8> PMID: 30002421
- Marinello S, Marini G, Parisi G, Gottardello L, Rossi L, Besutti V, et al. *Vibrio cholerae* non-O1, non-O139 bacteraemia associated with pneumonia, Italy 2016. *Infection*. 2017;45(2):237-40. <https://doi.org/10.1007/s15010-016-0961-4> PMID: 27837335
- Thodis E, Kriki P, Kakagia D, Passadakis P, Theodoridis M, Mourvati E, et al. Rigorous *Vibrio vulnificus* soft tissue infection of the lower leg in a renal transplant patient managed by vacuum therapy and autologous growth factors. *J Cutan Med Surg*. 2009;13(4):209-14. <https://doi.org/10.2310/7750.2008.08033> PMID: 19706229
- Brehm TT, Berneking L, Rohde H, Chistner M, Schlickewei C, Sena Martins M, et al. Wound infection with *Vibrio harveyi* following a traumatic leg amputation after a motorboat propeller injury in Mallorca, Spain: a case report and review of literature. *BMC Infect Dis*. 2020;20(1):104. <https://doi.org/10.1186/s12879-020-4789-2> PMID: 32019500
- Reilly GD, Reilly CA, Smith EG, Baker-Austin C. *Vibrio alginolyticus*-associated wound infection acquired in British waters, Guernsey, July 2011. *Euro Surveill*. 2011;16(42):19994. <https://doi.org/10.2807/ese.16.42.19994-en> PMID: 22027377
- Engel MF, Muijsken MA, Mooi-Kokenberg E, Kuijper EJ, van Westerloo DJ. *Vibrio cholerae* non-O1 bacteraemia: description of three cases in the Netherlands and a literature review. *Euro Surveill*. 2016;21(15). <https://doi.org/10.2807/1560-7917.ES.2016.21.15.30197> PMID: 27104237
- De Keukeleire S, Hoste P, Crivits M, Hammami N, Piette A. Atypical manifestation of *Vibrio cholerae*: fear the water! *Acta Clin Belg*. 2018;73(6):462-4. <https://doi.org/10.1080/17843286.2018.1483563> PMID: 29916306
- Stypulkowska-Misiurewicz H, Pancer K, Roszkowiak A. Two unrelated cases of septicaemia due to *Vibrio cholerae* non-O1, non-O139 in Poland, July and August 2006. *Euro Surveill*. 2006;11(11):E061130.2. PMID: 17213560
- Dalsgaard A, Frimodt-Møller N, Bruun B, Høi L, Larsen JL. Clinical manifestations and molecular epidemiology of *Vibrio vulnificus* infections in Denmark. *Eur J Clin Microbiol Infect Dis*. 1996;15(3):227-32. <https://doi.org/10.1007/BF01591359> PMID: 8740858
- Martínez-Urtaza J, Trinanés J, Abanto M, Lozano-Leon A, Llovo-Taboada J, García-Campello M, et al. Epidemic dynamics of *Vibrio parahaemolyticus* illness in a hotspot of disease emergence, Galicia, Spain. *Emerg Infect Dis*. 2018;24(5):852-9. <https://doi.org/10.3201/eid2405.171700> PMID: 29664388
- Baker-Austin C, Trinanés JA, Salmenlinna S, Löfdahl M, Siitonen A, Taylor NG, et al. Heat wave-associated *Vibriosis*, Sweden and Finland, 2014. *Emerg Infect Dis*. 2016;22(7):1216-20. <https://doi.org/10.3201/eid2207.151996> PMID: 27314874
- Frank C, Littman M, Alpers K, Hallauer J. *Vibrio vulnificus* wound infections after contact with the Baltic Sea, Germany. *Euro Surveill*. 2006;11(8):E060817.1. <https://doi.org/10.2807/esw.11.33.03024-en> PMID: 16966781
- Hoyer J, Engelmann E, Liehr RM, Distler A, Hahn H, Shimada T. Septic shock due to *Vibrio vulnificus* serogroup O4 wound infection acquired from the Baltic Sea. *Eur J Clin Microbiol Infect Dis*. 1995;14(11):1016-8. <https://doi.org/10.1007/BF01691388> PMID: 8654441
- Kuhnt-Lenz K, Krengel S, Fetscher S, Heer-Sonderhoff A, Solbach W. Sepsis with bullous necrotizing skin lesions due to *Vibrio vulnificus* acquired through recreational activities in the Baltic Sea. *Eur J Clin Microbiol Infect Dis*. 2004;23(1):49-52. <https://doi.org/10.1007/s10096-003-1056-6> PMID: 14655036
- Ruppert J, Panzig B, Guertler L, Hinz P, Schwesinger G, Felix SB, et al. Two cases of severe sepsis due to *Vibrio vulnificus* wound infection acquired in the Baltic Sea. *Eur J Clin Microbiol Infect Dis*. 2004;23(12):912-5. <https://doi.org/10.1007/s10096-004-1241-2> PMID: 15599654
- Lee LH, Ab Mutalib NS, Law JW, Wong SH, Letchumanan V. Discovery on antibiotic resistance patterns of *Vibrio parahaemolyticus* in Selangor reveals carbapenemase producing *Vibrio parahaemolyticus* in marine and freshwater fish. *Front Microbiol*. 2018;9:2513. <https://doi.org/10.3389/fmicb.2018.02513> PMID: 30410472
- Bier N, Schwartz K, Guerra B, Strauch E. Survey on antimicrobial resistance patterns in *Vibrio vulnificus* and *Vibrio cholerae* non-O1/non-O139 in Germany reveals carbapenemase-producing *Vibrio cholerae* in coastal waters. *Front Microbiol*. 2015;6:1179. <https://doi.org/10.3389/fmicb.2015.01179> PMID: 26579088
- Dupke S, Akinsinde KA, Grunow R, Iwalokun BA, Olukoya DK, Oluwadun A, et al. Characterization of *Vibrio cholerae* strains isolated from the Nigerian cholera outbreak in 2010. *J Clin Microbiol*. 2016;54(10):2618-21. <https://doi.org/10.1128/JCM.01467-16> PMID: 27487957
- Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. Guideline - Second Edition. Pennsylvania: CLSI. 2010;30(18). M45-A2.
- Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol*. 2012;19(5):455-77. <https://doi.org/10.1089/cmb.2012.0021> PMID: 22506599
- Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics*. 2014;30(14):2068-9. <https://doi.org/10.1093/bioinformatics/btu153> PMID: 24642063
- Yoon SH, Ha SM, Kwon S, Lim J, Kim Y, Seo H, et al. Introducing EzBioCloud: a taxonomically united database of 16S rRNA gene sequences and whole-genome assemblies. *Int J Syst Evol Microbiol*. 2017;67(5):1613-7. <https://doi.org/10.1099/ijsem.0.001755> PMID: 28005526
- Tamura K, Stecher G, Peterson D, Filipinski A, Kumar S. MEGA6: Molecular evolutionary genetics analysis version 6.0. *Mol Biol Evol*. 2013;30(12):2725-9. <https://doi.org/10.1093/molbev/mst197> PMID: 24132122
- Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. *Mol Biol Evol*. 1987;4(4):406-25. PMID: 3447015
- Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, et al. VFDB: a reference database for bacterial virulence factors. *Nucleic Acids Res*. 2005;33(Database issue):D325-8. <https://doi.org/10.1093/nar/gkio08> PMID: 15608208
- National Centers for Environmental Information. National Oceanic and Atmospheric Administration (NCEI.NOAA). NOAA o.25-degree daily optimum interpolation sea surface temperature (OISST), version 2.1. Washington: NCEI.NOAA.

- [Accessed: 6 Nov 2020]. Available from: <https://www.ncei.noaa.gov/metadata/geoportal/rest/metadata/item/gov.noaa.ncdc:C01606/html>
32. Shaw KS, Rosenberg Goldstein RE, He X, Jacobs JM, Crump BC, Sapkota AR. Antimicrobial susceptibility of *Vibrio vulnificus* and *Vibrio parahaemolyticus* recovered from recreational and commercial areas of Chesapeake Bay and Maryland Coastal Bays. *PLoS One*. 2014;9(2):e89616. <https://doi.org/10.1371/journal.pone.0089616> PMID: 24586914
  33. Lin HV, Massam-Wu T, Lin CP, Wang YA, Shen YC, Lu WJ, et al. The *Vibrio cholerae* var *regulon* encodes a metallo- $\beta$ -lactamase and an antibiotic efflux pump, which are regulated by VarR, a LysR-type transcription factor. *PLoS One*. 2017;12(9):e0184255. <https://doi.org/10.1371/journal.pone.0184255> PMID: 28898293
  34. López-Pérez M, Jayakumar JM, Haro-Moreno JM, Zaragoza-Solas A, Reddi G, Rodriguez-Valera F, et al. Evolutionary model of cluster divergence of the emergent marine pathogen *Vibrio vulnificus*: from genotype to ecotype. *MBio*. 2019;10(1):e02852-18. <https://doi.org/10.1128/mBio.02852-18> PMID: 30782660
  35. Nonaka L, Suzuki S. New Mg<sup>2+</sup>-dependent oxytetracycline resistance determinant tet 34 in *Vibrio* isolates from marine fish intestinal contents. *Antimicrob Agents Chemother*. 2002;46(5):1550-2. <https://doi.org/10.1128/AAC.46.5.1550-1552.2002> PMID: 11959596
  36. Zhang Z, Yu YX, Jiang Y, Wang YG, Liao MJ, Rong XJ, et al. First report of isolation and complete genome of *Vibrio rotiferianus* strain SSVR1601 from cage-cultured black rockfish (*Sebastes schlegelii*) associated with skin ulcer. *J Fish Dis*. 2019;42(5):623-30. <https://doi.org/10.1111/jfd.12963> PMID: 30851004
  37. Dechet AM, Yu PA, Koram N, Painter J. Nonfoodborne *Vibrio* infections: an important cause of morbidity and mortality in the United States, 1997-2006. *Clin Infect Dis*. 2008;46(7):970-6. <https://doi.org/10.1086/529148> PMID: 18444811
  38. Heng S-P, Letchumanan V, Deng C-Y, Ab Mutalib N-S, Khan TM, Chuah L-H, et al. *Vibrio vulnificus*: an environmental and clinical burden. *Front Microbiol*. 2017;8:997. <https://doi.org/10.3389/fmicb.2017.00997> PMID: 28620366
  39. Merkel SM, Alexander S, Zufall E, Oliver JD, Huet-Hudson YM. Essential role for estrogen in protection against *Vibrio vulnificus*-induced endotoxic shock. *Infect Immun*. 2001;69(10):6119-22. <https://doi.org/10.1128/IAI.69.10.6119-6122.2001> PMID: 11553550
  40. Hirk S, Huhulescu S, Allerberger F, Lepuschitz S, Rehak S, Weil S, et al. Necrotizing fasciitis due to *Vibrio cholerae* non-O1/non-O139 after exposure to Austrian bathing sites. *Wien Klin Wochenschr*. 2016;128(3-4):141-5. <https://doi.org/10.1007/s00508-015-0944-y> PMID: 26825075
  41. Semenza JC, Trinanes J, Lohr W, Sudre B, Löfdahl M, Martinez-Urtaza J, et al. Environmental suitability of *Vibrio* infections in a warming climate: an early warning system. *Environ Health Perspect*. 2017;125(10):107004. <https://doi.org/10.1289/EHP2198> PMID: 29017986
  42. Kniebusch M, Meier HEM, Neumann T, Börgel F. Temperature variability of the Baltic Sea since 1850 and attribution to atmospheric forcing variables. *J Geophys Res Oceans*. 2019;124(6):4168-87. <https://doi.org/10.1029/2018JC013948>
  43. Stramska M, Białogrodzka J. Spatial and temporal variability of sea surface temperature in the Baltic Sea based on 32-years (1982-2013) of satellite data. *Oceanologia*. 2015;57(3):223-35. <https://doi.org/10.1016/j.oceano.2015.04.004>
  44. Semenza JC, Herbst S, Rechenburg A, Suk JE, Höser C, Schreiber C, et al. Climate change impact assessment of food- and waterborne diseases. *Crit Rev Environ Sci Technol*. 2012;42(8):857-90. <https://doi.org/10.1080/10643389.2010.534706> PMID: 24808720
  45. Böer SI, Heinemeyer EA, Luden K, Erler R, Gerdt G, Janssen F, et al. Temporal and spatial distribution patterns of potentially pathogenic *Vibrio* spp. at recreational beaches of the German north sea. *Microb Ecol*. 2013;65(4):1052-67. <https://doi.org/10.1007/s00248-013-0221-4> PMID: 23563708
  46. Lee TH, Kim MH, Lee CS, Lee JH, Rhee JH, Chung KM. Protection against *Vibrio vulnificus* infection by active and passive immunization with the C-terminal region of the RtxA1/MARTXVv protein. *Vaccine*. 2014;32(2):271-6. <https://doi.org/10.1016/j.vaccine.2013.11.019> PMID: 24252692
  47. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2014;59(2):e10-52. <https://doi.org/10.1093/cid/ciu296> PMID: 24973422
  48. Roig FJ, González-Candelas F, Sanjuán E, Fouz B, Feil EJ, Llorens C, et al. Phylogeny of *Vibrio vulnificus* from the analysis of the core-genome: implications for intra-species taxonomy. *Front Microbiol*. 2018;8:2613. <https://doi.org/10.3389/fmicb.2017.02613> PMID: 29358930
  49. Newton A, Kendall M, Vugia DJ, Henao OL, Mahon BE. Increasing rates of vibriosis in the United States, 1996-2010: review of surveillance data from 2 systems. *Clin Infect Dis*. 2012;54 Suppl 5(S5):S391-5.

### License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2021.